Search / Trial NCT06225206

Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

Launched by METHODIST HEALTH SYSTEM · Jan 16, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Description

dd-cfDNA is a non-invasive method to measure graft function stability in liver transplant patients. Liver biopsy is the standard to determine liver rejection and graft function, but no tests exist currently to be able to help guide the IS regimen in these patients. LFTs are not as specific to determine graft function hence testing dd-cfDNA levels can help guide the Immunosuppression (IS )medications dosing and help identify rejection early.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age: ≥18 years
  • 2. The patient underwent a liver transplant.
  • 3. The patient at least has one level of dd-cfDNA documented
  • Exclusion Criteria:
  • * Patient not meeting the inclusion criteria will be excluded.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Dallas, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0